
Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target
Processa Pharmaceuticals (PCSA) Analyst Ratings
Bulls say
Processa Pharmaceuticals Inc. is projected to narrow its net loss per share estimate for 2026 to $0.15, an improvement from the previous estimate of $0.20, indicating enhanced financial management despite an increase in the outstanding share count. The anticipated positive interim data from the mid-stage trial of its NGC-Cap treatment is viewed as a potential significant value inflection point for the company. Additionally, the recent strategic investment and exploration of cryptocurrency treasury strategies suggest a proactive approach to enhancing financial stability and executing growth objectives.
Bears say
Processa Pharmaceuticals is projected to incur a significant net loss of $0.43 per share for the full year 2025, highlighting concerns about its financial sustainability. The company faces multiple risks, including potential delays in regulatory approvals, heightened competition which may lead to lower pricing and market penetration, and possible dilution risks that could negatively impact shareholder value. Additionally, a recent performance indicated a net loss of $0.25 per share, which, although close to earlier estimates, reaffirms the challenges the company faces in achieving profitability amidst a competitive landscape.
This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Processa Pharmaceuticals (PCSA) Analyst Forecast & Price Prediction
Start investing in Processa Pharmaceuticals (PCSA)
Order type
Buy in
Order amount
Est. shares
0 shares